Anatomic Pathology Service, Hematology Service and Translational Hematopathology Lab, Hospital Universitario Marques de Valdecilla/IDIVAL. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Santander, Cantabria, Spain.
Centre Nacional d'Anàlisi Genòmica (CNAG-CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
J Clin Pathol. 2020 Sep;73(9):571-577. doi: 10.1136/jclinpath-2019-206282. Epub 2020 Jan 24.
The aim of this study was to describe the characteristics of the bone marrow infiltration found in a series of clinically defined lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinaemia (WM) and IgM-monoclonal gammopathy of undetermined significance (MGUS) and to perform a targeted next-generation sequencing (NGS) for the identification of additional somatic mutations to p.L265P in LPL/WM.
We have reviewed a series of 35 bone marrow biopsies from 28 patients with a clinical diagnosis of LPL/WM (24 cases) or MGUS (4 cases). Bone marrow infiltration characteristics by morphology, immunohistochemistry, flow cytometry (FCM), allele-specific real-time PCR for the detection of p.L265P mutation, targeted exonic amplicon-based NGS of 35 lymphoma-related genes and direct sequencing were analysed.
Our findings show that bone marrow trephine biopsy evaluation is superior to FCM in the identification of significant lymphoid infiltrates. A combined paratrabecular and interstitial infiltration pattern is the most common feature in LPL/WM while a patchy interstitial pattern characterises IgM-MGUS cases. p.L265P mutation was found by allele-specific-PCR in 92% of the LPL cases (22 out of 24) and 25% of IgM-MGUS cases (1 out of 4 cases). In addition to p.L265P somatic mutations in , , /Blimp1, and were found by NGS and direct sequencing in 4 cases.
In conclusion, bone marrow core biopsy evaluation is critical in the identification of unequivocal bone marrow infiltration by LPL/WM. In addition to p.L265P, somatic mutations in , , /Blimp1, and can appear in a fraction of LPL/WM.
本研究旨在描述一系列临床定义的淋巴浆细胞淋巴瘤(LPL)/华氏巨球蛋白血症(WM)和 IgM 单克隆丙种球蛋白血症不明意义(MGUS)中骨髓浸润的特征,并对 LPL/WM 中的 p.L265P 进行靶向下一代测序(NGS)以鉴定其他体细胞突变。
我们回顾了 28 例临床诊断为 LPL/WM(24 例)或 MGUS(4 例)患者的 35 例骨髓活检。通过形态学、免疫组织化学、流式细胞术(FCM)、检测 p.L265P 突变的等位基因特异性实时 PCR、35 个淋巴瘤相关基因的靶向外显子扩增子 NGS 和直接测序分析骨髓浸润特征。
我们的研究结果表明,骨髓活检评估在识别明显的淋巴样浸润方面优于 FCM。LPL/WM 中最常见的特征是小梁旁和间质联合浸润模式,而 IgM-MGUS 病例则表现为局灶性间质浸润模式。通过等位基因特异性 PCR 在 92%的 LPL 病例(22 例中的 22 例)和 25%的 IgM-MGUS 病例(4 例中的 1 例)中发现了 p.L265P 突变。通过 NGS 和直接测序在 4 例中发现了除 p.L265P 体细胞突变外,还存在于 、 、 /Blimp1 和 中的突变。
总之,骨髓核心活检评估对于明确 LPL/WM 的骨髓浸润至关重要。除了 p.L265P 外,在 LPL/WM 中还存在于 、 、 /Blimp1 和 中的体细胞突变。